Abivax

123 articles with Abivax

• Abivax Publishes Universal Registration Document 2022 'Document d'Enregistrement Universel'

  4/28/2022

  Abivax SA announces the publication of its 2022 Universal Registration Document, filed with the French Financial Market Authorities, Autorité des Marchés Financiers, on April 28, 2022.

• 

  Clinical Catch-Up: COVID-19, AAN, ACC

  4/11/2022

  It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.

• Abivax Reports Excellent One-Year Efficacy and Safety Data of ABX464 Phase 2b Maintenance Trial in Ulcerative Colitis

  4/6/2022

  Abivax SA today reports excellent results from the Interim Analysis of its phase 2b open-label maintenance study, including 217 patients who completed the one year of once-daily oral treatment with 50mg ABX464.

• Abivax Reports 2021 Financial Results and Operations Update

  3/16/2022

  Abivax SA announces its 2021 annual financial results, as of December 31, 2021, and provides an update on the progress of its product pipeline.

• Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results in Rheumatoid Arthritis

  3/10/2022

  Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, reports promising results from its phase 2a maintenance trial in rheumatoid arthritis after one year of continued daily treatment with 50mg ABX464.

• Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022

  2/8/2022

  Abivax will be hosting a Satellite Symposium on February 17, 2022, at 12:00-1:00 pm CET (6:00-7:00am ET) on ABX464's potential to address unmet medical needs for the treatment of ulcerative colitis (UC).

• Abivax 2022 Financial Communication Calendar

  1/25/2022

  Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases and cancer, publishes its 2022 financial communication calendar.

• 

  Clinical Catch-Up: January 17-21

  1/24/2022

  Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look.
• 

  Global Roundup: UCB Snaps Up Rare Disease Company Zogenix

  1/20/2022

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer to be Presented on Jan. 21, at ASCO GI Cancers Symposium 2022

  1/19/2022

  Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces the detailed results of the dose escalation phase of its clinical phase 1/2 study conducted with ABX196 for the treatment of hepatocellular carcinoma, to be presented at the ASCO GI Cancers Symposium on January 20-22, 2022.

• 

  Clinical Catch-Up: January 10-14

  1/17/2022

  Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.

• Abivax Receives EMA Scientific Advice Supportive of Moving ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

  1/13/2022

  Abivax SA announced that the European Medicines Agency provided their feedback in the context of the scientific advice meeting that supports advancing ABX464 into phase 3 clinical testing for the treatment of ulcerative colitis and subsequent potential marketing authorization submission and commercialization.

• Abivax to Present at the J.P. Morgan 40th Annual Healthcare Conference

  12/15/2021

  Abivax SA announces that Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, will present at the J.P. Morgan 40th Annual Healthcare Conference on Thursday, January 13, 2022 at 12:00-12:40 pm ET.

• 

  Clinical Catch-Up: November 29-December 3

  12/6/2021

  Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.

• Abivax Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

  12/1/2021

  End-of-phase-2 response from the US regulatory agency (FDA) provides guidance and a path forward to advance ABX464 into a phase 3 clinical program in ulcerative colitis (UC).

• Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer Show Good Tolerability and Promising Signals of Clinical Benefit and were Selected for Presentation at the ASCO GI Cancers Symposium 2022

  11/30/2021

  Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, reports the good tolerability and promising signals of clinical benefit resulting from its clinical phase 1/2 study conducted with ABX196.

• 

  Clinical Catch-Up: October 18-22

  10/25/2021

  It was yet another busy week for clinical trial news. Here’s a look.

• ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis

  10/18/2021

  Abivax SA today reports new results from an extended set of patients in its ongoing open-label maintenance study, following the phase 2b induction study of once-daily oral 50mg ABX464 to treat ulcerative colitis (UC).

• Abivax Late-Breaking Abstract Presentation and Live Industry Symposium at the UEG Week Virtual 2021

  9/28/2021

  Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, would like to invite you to attend the Abivax late-breaking abstract presentation as well as the Abivax Live Industry Symposium at the UEG Week Virtual 2021.

• Abivax Presents First-half 2021 Financial Results and Operations Update

  9/23/2021

  In May and September, Abivax reported excellent efficacy and safety results of once daily oral ABX464 in a phase 2b induction study in ulcerative colitis (UC) after 8 and 16 weeks of treatment, primary and key secondary endpoints were met